Skip to main content
Natco Pharma Ltd. logo

Natco Pharma Ltd. — Investor Relations & Filings

Ticker · NATCOPHARM ISIN · INE987B01026 LEI · 33580086GIBRWXSNGG39 BSE.NS Manufacturing
Filings indexed 1,707 across all filing types
Latest filing 2022-02-14 Board/Management Inform…
Country IN India
Listing BSE.NS NATCOPHARM

About Natco Pharma Ltd.

https://www.natcopharma.co.in/

Natco Pharma Ltd. is a vertically integrated organization focused on the development, manufacturing, and marketing of complex generics and active pharmaceutical ingredients (APIs). The company specializes in niche therapeutic areas, maintaining a leadership position in oncology and a significant presence in specialty segments such as hepatology, cardiology, and diabetology. Natco is recognized for its expertise in high-barrier-to-entry products, including complex oral solids and injectables. Its business model emphasizes research and development to deliver affordable versions of life-saving medicines globally. With a robust portfolio of finished dosage formulations and a strong supply chain for APIs, the company serves diverse international markets, including North America, Europe, and emerging economies, through strategic partnerships and direct distribution channels.

Recent filings

Filing Released Lang Actions
Record Date
Board/Management Information Classification · 95% confidence The document contains a table listing directors with their DIN numbers and designations, indicating it is related to board or management information. There is no financial data, no mention of reports, votes, or other regulatory filings. The document length is short (584 characters), and it focuses on personnel details rather than financial or governance reports. Therefore, it fits best under Board/Management Information (MANG).
2022-02-14 English
Un audited Financial Results for the Quarter ended 31st December, 2021
Regulatory Filings
2022-02-14 English
Financial Result Updates
Regulatory Filings
2022-02-14 English
Earnings Call with Investors / Analysts at 11.00 a.m. IST on Tuesday, February 15, 2022,
Regulatory Filings
2022-02-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 80% confidence The document is a short announcement dated February 9, 2022, informing about an upcoming earnings call scheduled for February 15, 2022, to discuss the financial results for the quarter ended December 31, 2021 (Q3 FY22). It includes dial-in details and contact information but does not contain any actual financial data or detailed financial results. The document is under 5,000 characters and serves as a notice for the earnings call rather than the call transcript or the earnings release itself. Therefore, it is best classified as a Call Transcript (CT) announcement or related to earnings call scheduling. However, since it is only announcing the call and not the transcript, the closest fitting category is Call Transcript (CT) with moderate confidence, as it is about the earnings call event.
2022-02-09 English
TRADING WINDOW for dealing in the securities of the Company by the Employee(s), connected persons and their immediate relatives will be closed from 5th February, 2022 to 16th February, ....
Regulatory Filings
2022-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.